Financhill
Back

Prime Medicine Quote, Financials, Valuation and Earnings

Prime Medicine Price Quote

$3.67
-0.29 (-7.32%)
(Updated: November 14, 2024 at 11:55 AM ET)

Prime Medicine Key Stats

Sell
39
Prime Medicine (PRME) is a Sell

Day range:
$3.96 - $4.49
52-week range:
$3.28 - $9.86
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.64%

Volume:
1.5M
Avg. volume:
1.1M
1-year change:
-40.59%
Market cap:
$518.5M
Revenue:
$0
EPS:
$-2.17

How Much Does Prime Medicine Make?

Data Unavailable

Is Prime Medicine Growing As A Company?

Data Unavailable

Prime Medicine Stock Price Performance

  • Did Prime Medicine Stock Go Up Last Month?
    Prime Medicine share price went up by 8.79% last month
  • Did PRME's Share Price Rise Over The Last Year?
    PRME share price fell by -40.59% over the past 1 year

What Is Prime Medicine 52-Week High & Low?

Prime Medicine Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Prime Medicine?

  • How Much Debt Does Prime Medicine Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Prime Medicine Have?
    Cash and short term investments quarterly total is $162.9M
  • What Is Prime Medicine’s Book Value Per Share?
    Book value per share is 1.64

Is Prime Medicine Cash Flow Positive?

  • What Is PRME Cash Flow From Operations?
    Cash flow from operations (TTM) is -$196.2M
  • What Is Prime Medicine’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $157.9M
  • What Is Prime Medicine’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$26.6M

Prime Medicine Return On Invested Capital

Data Unavailable

Prime Medicine Earnings Date & Stock Price

Prime Medicine Competitors

  • Who Are Prime Medicine's Competitors?
    Below is a list of companies who compete with Prime Medicine or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Bristol-Myers Squibb Co (BMY)
    • CEL-SCI Corp (CVM)
    • IGC Pharma Inc (IGC)
    • Molecular Templates Inc (MTEM)

Prime Medicine Dividend Yield

Prime Medicine Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -18.85%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 12.91
Upside from Last Price: 225.99%

Major Shareholders

  • How many PRME shares are owned by institutional investors?
    92.2M PRME shares are owned by institutional investors
  • How many PRME shares are owned by insiders?
    3.5M PRME shares are owned by insiders